28 February 2025
Physiomics plc
("Physiomics" or "the Company")
Notice of Results and Investor
Presentation
Physiomics plc (AIM: PYC), a leading
mathematical modelling, data science and biostatistics company
supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce that it
will be posting interim results on Thursday 6 March
2025.
The Company will provide a live
presentation in-line with these results via Investor
Meet Company on 10 March 2025 at 12:00 pm GMT. During this
presentation, Peter Sargent (CEO) and Jim Millen (Chairman) would
be happy to take questions relating to our interim results and more
broadly about the business.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9 March
2025, 09:00 am GMT, or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet PHYSIOMICS PLC
via:
https://www.investormeetcompany.com/physiomics-plc/register-investor
Investors who already follow
PHYSIOMICS PLC on the Investor Meet Company platform will
automatically be invited.
Enquiries:
Physiomics
plc
Dr Peter Sargent, Chief Executive Officer, +44
(0)1865 784 980
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
